Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a regenerative medicine company with a focus on advanced wound care and sports medicine markets, whose product portfolio includes a range of established solutions such as Apligraf and Dermagraft. Despite facing mixed performance due to market dynamics and impending changes in reimbursement structures, the company is expected to achieve improved operating profits and valuation as it continues to produce solid results. Projections suggest that as reimbursement rates stabilize and the market consolidates, Organogenesis Holdings is well-positioned to capture additional market share, contributing to a positive outlook for its stock.

Bears say

Organogenesis Holdings Inc. faces significant headwinds that contribute to a negative outlook, primarily due to the anticipated lack of improvement in operational efficiency, particularly concerning research and development costs in FY26. Additionally, the company is vulnerable to various external risks, including potential underperformance in PuraPly sales, unfavorable Medicare Part B pricing for amniotic products, and increased competition that may hinder market share growth. Lastly, challenges from Medicare Administrative Contractors, slow adoption of new products, and adverse clinical data outcomes further exacerbate the concerns regarding the company's future financial performance.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.